Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LentiGlobin BB305 in Beta-Thalassemia and Sickle Cell Disease
NCT02151526Phase 2Completed
- Sponsor
- bluebird bio, Inc.
- Start
- Jun 2013
- Primary completion
- Feb 2019
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of betibeglogene autotemcel in beta thalassemia, sickle cell disease (SCD), sponsored by bluebird bio, Inc.. Started Jun 2013; status: completed.
02
Drugs
betibeglogene autotemcel
03
Conditions
beta thalassemiasickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02151526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151526.